^
    Back
    Association details:
    Biomarker:ALK positive
    Cancer:Non-Hodgkin’s Lymphoma
    Drug:Zykadia (ceritinib) (ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2021
    Title:

    ALK Inhibitor Plus Vinblasitine for Refractory/Relapsed Pediatric ALK+ Anaplastic Large Cell Lymphoma: A Prospective, One-Arm, Open-Label Real-World Study

    Published date:
    11/04/2021
    Excerpt:
    To assess the efficacy and safety of ALK inhibitors combined with VBL in pediatric relapsed/refractory (r/r) ALK+ ALCL....ALK inhibitors included crizotinib(CZ), alectinib(AL) and ceritinib(CER)....After 1st cycle of treatments, 62.9%(17/26) achieved comlpele remission(CR) without measurable tumors and ALK gene transcription, no progressed cases.... ALK inhibitors combined with VBL may rapidly induce the tumor remission of r/r ALK+ALCL and the tolerance is good.
    Secondary therapy:
    vinblastine
    DOI:
    10.1182/blood-2021-149402